| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Product Type | |
| Shipping | |
| Species | |
| Storage | |
| UniProt # |
Scientific Background
CD37 expression is restricted to cells of the immune system, with highest abundance on mature B cells, and lower expression is found on T cells and myeloid cells. CD37 is a cell surface glycoprotein that is known to complex with integrins and other transmembrane 4 superfamily proteins. It is also expressed in B-cell non-Hodgkin Lymphomas, in chronic lymphocytic leukemia (CLL), and in some cases of cutaneous and peripheral T-cell lymphomas. CAR-37 T cells have demonstrated antigen-specific activation, cytokine production, and cytotoxic activity in models of B- and T-cell lymphomas in vitro and in vivo, including patient-derived xenografts. T cells expressing anti-CD37 CAR have substantial activity against 2 different lymphoid lineages, without evidence of significant T cell fratricide. Furthermore, anti-CD37 CARs have been combined with anti-CD19 CARs to generate dual-specific CAR T cells capable of recognizing CD19 and CD37 alone or in combination. CD37-CAR T cells represent a novel therapeutic agent for the treatment of patients with CD37-expressing lymphoid malignancies.
Product Description
CAR T-Cell TherapyRecombinant clonal stable CHO cell line constitutively expressing full length human CD37 protein, also known as GP52-40; TSPAN26; leukocyte antigen CD37 (Genbank #NM_001774). Surface expression of CD37 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of CD37 expression, (High, Medium, Low), to mimic different stages of cancer target cells with various CD37 expression levels.
Product Specifications
| Host Cell Line | CHO |
|---|---|
| Host Species | Hamster |
| Transfection Method | Lipofectamine 2000 |
| Supplied As | Each vial contains ~ 2 x 10^6 cells in 1 ml of 10% DMSO in FBS. |
| Harmonized Tariff Code | 3002-5900 |
Quality Control & Validation
✓ Mycoplasma-TestedThis cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control.
Usage Notes
See data sheet for detailed culturing and assay protocol.
Safety & Handling
⚠ Avoid freeze/thaw cycles.
Regulatory Information
License Disclosure
Related Products
Related Products: Cat. #101330, 79561
Required Accessories: Cat. #79539,60186, 79796
This product is engineered on a CHO background (Human origin). The CHO host was selected for its compatibility with stable transfection and the target pathway or assay type. Consult the product datasheet for passage number guidance and recommended culture media.
This product is classified as BSL-1. Standard microbiological practices (gloves, lab coat, eye protection) are sufficient. No specialized containment facility is required beyond a clean bench. Consult your institutional IBC for GMO registration requirements.
Yes. This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control. We recommend that you independently confirm mycoplasma-negative status after receipt and periodically during routine culture using a validated detection kit.
Store this product at Liquid Nitrogen. Specifically: Store in liquid nitrogen immediately upon receipt. Transfer cells from dry-ice shipping to the recommended storage immediately upon receipt. Avoid repeated freeze-thaw cycles, which reduce viability and may alter expression characteristics.
Yes, a license is required (Yes). Purchase of this cell line grants a time-limited research-use license for use in your immediate laboratory only. This license does not permit redistribution, sub-licensing, transfer to other institutions, or commercial use. Refer to the License Disclosure section on this page or contact BPS Bioscience for details regarding modifications or commercial licensing.
This stable cell line was generated using Lipofectamine 2000 for transgene delivery into the parental host. The stably integrated cells were selected using the appropriate resistance marker and verified for expression prior to cryopreservation.
Can't find the cell line you need—or require a custom engineered model for your study? We offer end-to-end support for diverse research needs, including:
- Cell line sourcing and selection (species, tissue, and disease model matching)
- Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA)
- Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs)
- Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles)
- Inducible expression systems (Tet-On/Off and regulatable constructs)
- Drug resistance marker selection (puromycin, G418, hygromycin, and others)
- Custom growth and media optimisation for specific assay requirements
- Scale-up production for high-throughput screening campaigns
- Authentication and QC services (STR profiling, mycoplasma testing, viability assessment)
Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
- Scarfò, I. et al. Anti-CD37 chimeric antigen receptor T cells are active against B and T cell lymphomas. Blood. 2018 Oct; 132(14):1495-1506 2. Witkowska, M. et al. Investigational therapies targeting CD37 for the treatment of Bcell lymphoid malignancies. Expert Opin Investig Drugs. 2018 Feb;27(2):171-177